Stockscreener 앱 받기
2.05
0.99%
0.02
전일 마감가:
$2.03
열려 있는:
$2.04
하루 거래량:
117.08K
Relative Volume:
0.86
시가총액:
$68.98M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-1.5272
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
-0.49%
1개월 성능:
-14.94%
6개월 성능:
-21.15%
1년 성능:
-36.92%
1일 변동 폭
$1.99
$2.07
1주일 범위
$1.94
$2.2199
52주 변동 폭
$1.90
$4.21
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
VTGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
2.05 | 68.98M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair - MarketBeat
Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada
Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - GuruFocus
Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks
Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline - MSN
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - sharewise
Earnings call transcript: Vistagen’s focus on innovation amid rising expenses Q1 2025 - Investing.com India
Vistagen Therapeutics Inc Reports Q1 Revenue of $0.49M, Surpassi - GuruFocus
Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Vistagen (VTGN) Reports Decrease in FY25 Revenue, Advances Key Medical Programs | VTGN Stock News - GuruFocus
Vistagen Therapeutics, Inc. SEC 10-K Report - TradingView
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For - GuruFocus
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Holdings Increased by Millennium Management LLC - Defense World
Vistagen Therapeutics Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Vistagen Earnings Preview: Late-Stage Neuroscience Biotech to Unveil FY2025 Performance - Stock Titan
Two Sigma Investments LP Has $405,000 Position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Two Sigma Advisers LP Acquires New Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Vistagen Therapeutics (NASDAQ:VTGN) Earnings Preview: What to Expect from $VTGN Amid Shifting Investor Sentiment | VTGN Stock - paginasiete.bo
VISTAGEN THERAPEUTICS Earnings Preview: Recent $VTGN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Vistagen Therapeutics (VTGN) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
VistaGen at Jefferies: Expanding Horizons in Social Anxiety Treatment By Investing.com - Investing.com Canada
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp - Defense World
Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World
Vistagen expects phase 3 trial results by 2026 By Investing.com - Investing.com South Africa
Vistagen expects phase 3 trial results by 2026 - Investing.com India
VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN St - GuruFocus
VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN Stock News - GuruFocus
Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial - MarketScreener
Major Social Anxiety Treatment Breakthrough: Phase 3 Trial Results Coming Q4 2025What to Expect - Stock Titan
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - sharewise
Vistagen Showcases Revolutionary Nose-to-Brain Drug Technology at Major Jefferies Healthcare Conference - Stock Titan
Breakthrough Nasal Spray Treatment Shows Promise for Depression and Social Anxiety, New Clinical Data Reveals - Stock Titan
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference - BioSpace
Ellis Martin Report: Vistagen Therapeutics Inc. (NASDAQ:VTGN) CEO Shawn SinghA Revolutionary Fast Acting Nasal Spray Targeting Social Anxiety Disorder - ABN Newswire
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC - MarketBeat
254,655 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by Almitas Capital LLC - MarketBeat
Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Form 8-KCurrent report - ADVFN
Nantahala Capital Management LLC Boosts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat
JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - BioSpace
Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.02%
1.78%
자본화:
|
볼륨(24시간):